Article info

Effects of infliximab on lung and circulating natural killer cells, CD56+ T cells and B cells in sarcoidosis

Authors

  • Susanna Kullberg Department of Respiratory Medicine, Theme Inflammation and Ageing, Karolinska University Hospital, Stockholm, SwedenRespiratory Medicine Division, Department of Medicine, Karolinska Institute, Stockholm, Sweden PubMed articlesGoogle scholar articles
  • Natalia V Rivera Respiratory Medicine Division, Department of Medicine, Karolinska Institute, Stockholm, Sweden PubMed articlesGoogle scholar articles
  • Johan Grunewald Department of Respiratory Medicine, Theme Inflammation and Ageing, Karolinska University Hospital, Stockholm, SwedenRespiratory Medicine Division, Department of Medicine, Karolinska Institute, Stockholm, Sweden PubMed articlesGoogle scholar articles
  • Anders Eklund Department of Respiratory Medicine, Theme Inflammation and Ageing, Karolinska University Hospital, Stockholm, SwedenRespiratory Medicine Division, Department of Medicine, Karolinska Institute, Stockholm, Sweden PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Susanna Kullberg; susanna.kullberg{at}ki.se
View Full Text

Citation

Kullberg S, Rivera NV, Grunewald J, et al
Effects of infliximab on lung and circulating natural killer cells, CD56+ T cells and B cells in sarcoidosis

Publication history

  • Received March 24, 2021
  • Accepted May 15, 2021
  • First published July 7, 2021.
Online issue publication 
July 07, 2021
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.